N-Acetyl Glucosamine (NAG) and joints

What 2 graded rows on n-acetyl glucosamine (nag) agree on for joints, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the N-Acetyl Glucosamine (NAG) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the N-Acetyl Glucosamine (NAG) page, with its PubMed record.

Supplement

N-Acetyl Glucosamine (NAG) Choose another

2 rows · 118 people

Split. 1 row found no difference and 1 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade D, is a randomized trial of 68 people (2017) and found no difference.

The rows run from 50 to 68 people, published from 2016 to 2017: 2 single studies.

1 no difference · 1 mixed

Grade DCartilage turnover markers in healthy adults · No difference
RCT · n 68 · 2017 · Healthy Japanese adults without arthritis symptoms
500 or 1,000 mg/day · 16 weeks
No change in type II collagen breakdown or synthesis markers overall; in a subgroup with worse baseline markers, breakdown (C2C) fell versus placebo. No supplement-related adverse events.
Row on the N-Acetyl Glucosamine (NAG) page · PubMed 28413518 (opens PubMed)
Grade DKnee pain and self-reported knee function · Mixed
RCT · n 50 · 2016 · Japanese adults aged 52–87 with knee pain or stiffness (11 men, 39 women)
100 mg/day NAG with 180 mg/day chondroitin sulfate · 24 weeks
Self-reported knee function (JKOM score) improved versus placebo, significantly at 12 weeks, and household physical activity rose; pain on a 100 mm scale and physical performance tests did not differ.
Row on the N-Acetyl Glucosamine (NAG) page · PubMed 26178634 (opens PubMed)